Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890834 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL730345 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2 | |
| Fluoride SCHEMBL890954 | 0.99 | CHRM3 (0.99) | CHRM3ADRB2 | |
| SCHEMBL741158 | 0.99 | CHRM3 (1.00) | CHRM3ADRB2 | |
| Oxalic Acid SCHEMBL890700 | 0.98 | CHRM3 (0.97) | CHRM3ADRB2 | |
| Oxalic Acid SCHEMBL890698 | 0.98 | CHRM3 (0.97) | CHRM3ADRB2 | |
| Oxalic Acid SCHEMBL890819 | 0.98 | CHRM3 (0.96) | CHRM3ADRB2 | |
| Trifluoroacetic Acid SCHEMBL901073 | 0.97 | CHRM3 (0.94) | CHRM3ADRB2 | |
| Trifluoroacetic Acid SCHEMBL694506 | 0.97 | CHRM3 (0.94) | CHRM3ADRB2 | |
| Trifluoroacetic Acid SCHEMBL693877 | 0.96 | CHRM3 (0.94) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697724-B2 | Crystalline oxalate salts of a diamide compound | THERAVANCE, INC. (US) | 2014-04-15 | — | — | US | claimed |
| US-8551978-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE, INC. (US) | 2013-10-08 | — | — | US | claimed |
| US-20130137665-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE, INC. (US) | 2013-05-30 | — | — | US | claimed |
| EP-2421849-B1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE INC (US) | 2013-04-03 | — | — | EP | claimed |
| US-20120083478-A1 | CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND | THERAVANCE, INC. (US) | 2012-04-05 | — | — | US | claimed |
| US-8138345-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE, INC. (US) | 2012-03-20 | — | — | US | claimed |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-10-28 | — | — | US | claimed |
| JP-2015155470-A | CRYSTALLINE OXALATE SALTS OF DIAMIDE COMPOUND | セラヴァンス レスピラトリ カンパニー， エルエルシー | 2015-08-27 | — | — | JP | disclosed |
| US-8697724-B2 | Crystalline oxalate salts of a diamide compound | THERAVANCE, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697724-B2 | Crystalline oxalate salts of a diamide compound | THERAVANCE, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| JP-2013538857-A | — | — | 2013-10-17 | — | — | JP | disclosed |
| EP-2621917-A1 | CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND | Theravance, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044825-A1 | CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND | THERAVANCE, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120083478-A1 | CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND | THERAVANCE, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083478-A1 | CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND | THERAVANCE, INC. (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083478-A1 | CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND | OTC, PKD2, OAT | CHRM3 1794/4885ADRB2 3746/4885 |
| US-20100273755-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | CHRM3 13/4885ADRB2 1/4885 |
| US-20130137665-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2A | CHRM3 13/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.